The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
Open accessAbstract
The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled prostate-specific membrane antigen (PSMA)–617 therapy in a retrospectively analyzed group of patients. Methods: Forty patients with metastatic castration-resistant prostate cancer were selected for treatment with three 100 kBq/kg cycles of 225Ac-PSMA-617 at 2-mo intervals. Prostate-specific antigen (PSA) and blood cell count were measured every 4 wk. PSMA PET/CT or PSMA SPECT/CT were used for baseline staging and imaging follow-up at month 6. Follow-up included the duration of PSA response and radiologic progression-free survival at month 6. Patient histories were reviewed for the duration of previous treatment lines, and a swimmer plot was used to intraindividually compare the duration of tumor control by PSMA therapy versus prior treatment modalities. Results: Thirty-one of 40 patients were treated per protocol. Five patients discontinued treatment because of nonresponse, and 4 because of xerostomia. Of the 38 patients surviving at least 8 wk, 24 (63%) had a PSA decline of more than 50%, and 33 (87%) had a PSA response of any degree. The median duration of tumor control under 225Ac-PSMA-617 last-line therapy was 9.0 mo; 5 patients had an enduring response of more than 2 y. Because all patients had advanced disease, this result compares favorably with the tumor control rates associated with earlier-phase disease; the most common preceding first-, second-, third-, and fourth-line therapies were abiraterone (median duration 10.0 mo), docetaxel (6.5 mo), enzalutamide (6.5 mo), and cabazitaxel (6.0 mo), respectively. Conclusion: A positive response for surrogate parameters demonstrates remarkable antitumor activity for 225Ac-PSMA-617. Swimmer-plot analysis indicates a promising duration of tumor control, especially considering the unfavorable prognostic profile of the selected advanced-stage patients. Xerostomia was the main reason patients discontinued therapy or refused additional administrations and was in the same dimension as nonresponse; this finding indicates that further modifications of the treatment regimen with regard to side effects might be necessary to further enhance the therapeutic range.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 2×
“In ALSMYPCA (23), the only recent formal clinical trial that accepted patients who either had received docetaxel or were ineligible to receive it, 43% of the recruited patients had been declared unfit for chemotherapy by their supporting oncologist.”
BackgroundEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369 · cited 1×
“8 mo, respectively, in the postdocetaxel setting (28,29).”
BackgroundKratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,100
Self-citationBubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Kratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Self-citationBenešová, M., Schäfer, M., Bauder-Wüst, U., Afshar-Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147413 · Cited by 612
Self-citationBaum, R. P., Kulkarni, H. R., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., Schottelius, M., Mueller, D., Klette, I., & Wester, H.-J. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168443 · Cited by 525
Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505
Self-citationHalabi, S., Lin, C.-Y., Kelly, W. K., Fizazi, K. S., Moul, J. W., Kaplan, E. B., Morris, M. J., & Small, E. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3696 · Cited by 478
Noonan, K. L., North, S., Bitting, R. L., Armstrong, A. J., Ellard, S. L., & Chi, K. N. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt138 · Cited by 343
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
McDevitt, M. R., Barendswaard, E., Ma, D., Lai, L. T., Curcio, M. J., Sgouros, G., Ballangrud, Å., Yang, W., Finn, R. D., Pellegrini, V., et al. (2000) · PubMed · Cited by 259
Smith, M., De Bono, J., Sternberg, C., Le Moulec, S., Oudard, S., De Giorgi, U., Krainer, M., Bergman, A., Hoelzer, W., De Wit, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5597 · Cited by 249
Fendler, W. P., Reinhardt, S., Ilhan, H., Delker, A., Böning, G., Gildehaus, F. J., Stief, C., Bartenstein, P., Gratzke, C., Lehner, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.12240 · Cited by 223
Pili, R., Häggman, M., Stadler, W. M., Gingrich, J. R., Assikis, V. J., Björk, A., Nordle, Ö., Forsberg, G., Carducci, M. A., & Armstrong, A. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6295 · Cited by 207
Pond, G. R., Sonpavde, G., de Wit, R., Eisenberger, M. A., Tannock, I. F., & Armstrong, A. J. (2014) · European Urology · doi:10.1016/j.eururo.2013.09.024 · Cited by 193
Kulkarni, H. R., Singh, A., Schuchardt, C., Niepsch, K., Sayeg, M., Leshch, Y., Wester, H.-J., & Baum, R. P. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.170167 · Cited by 192
Heck, M. M., Retz, M., D'Alessandria, C., Rauscher, I., Scheidhauer, K., Maurer, T., Storz, E., Janssen, F., Schottelius, M., Wester, H.-J., et al. (2016) · Journal of Urology · doi:10.1016/j.juro.2016.02.2969 · Cited by 187
Bräuer, A., Grubert, L. S., Roll, W., Schrader, A. J., Schäfers, M., Bögemann, M., & Rahbar, K. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3751-z · Cited by 173
Ahmadzadehfar, H., Wegen, S., Yordanova, A., Fimmers, R., Kürpig, S., Eppard, E., Wei, X., Schlenkhoff, C., Hauser, S., & Essler, M. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3716-2 · Cited by 170
Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv594 · Cited by 167
Yadav, M. P., Ballal, S., Tripathi, M., Damle, N. A., Sahoo, R. K., Seth, A., & Bal, C. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3481-7 · Cited by 161
Sathekge, M. M., Knoesen, O., Meckel, M., Modiselle, M., Vorster, M., & Marx, S. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3657-9 · Cited by 147
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
Kratochwil, C., Schmidt, K. F., Afshar‐Oromieh, A., Bruchertseifer, F., Rathke, H. G., Morgenstern, A., Haberkorn, U., & Giesel, F. L. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3817-y · Cited by 145
Self-citationKiess, A. P., Minn, I., Vaidyanathan, G., Hobbs, R. F., Josefsson, A., Shen, C. J., Brummet, M. E., Chen, Y., Choi, J., Koumarianou, E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.174300 · Cited by 144
Badrising, S., van der Noort, V., van Oort, I. M., van den Berg, H. P., Los, M., Hamberg, P., Coenen, J. L., van den Eertwegh, A. J. M., de Jong, I. J., Kerver, E. D., et al. (2014) · Cancer · doi:10.1002/cncr.28518 · Cited by 136
Smith, M. R., Sweeney, C. J., Corn, P. G., Rathkopf, D. E., Smith, D. C., Hussain, M., George, D. J., Higano, C. S., Harzstark, A. L., Sartor, O. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5954 · Cited by 129
PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer
Kratochwil, C., Giesel, F. L., Leotta, K., Eder, M., Hoppe-Tich, T., Youssoufian, H., Kopka, K., Babich, J. W., & Haberkorn, U. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147181 · Cited by 117
Self-citationSternberg, C. N., Armstrong, A. J., Пили, Р., Ng, S. S. W., Huddart, R. A., Agarwal, N., Khvorostenko, D., Lyulko, O. O., Brize, A., Vogelzang, N. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9697 · Cited by 117
Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer
Gaertner, F. C., Halabi, K., Ahmadzadehfar, H., Kürpig, S., Eppard, E., Kotsikopoulos, C., Liakos, N., Bundschuh, R. A., Strunk, H. M., & Essler, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19049 · Cited by 112
Ballangrud, Å., Yang, W., Charlton, D. E., McDevitt, M. R., Hamacher, K. A., Panageas, K. S., Ma, D., Bander, N. H., Scheinberg, D. A., & Sgouros, G. (2001) · PubMed · Cited by 98
Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq
Rathke, H. G., Giesel, F. L., Flechsig, P., Kopka, K., Mier, W., Hohenfellner, M., Haberkorn, U., & Kratochwil, C. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.194209 · Cited by 93
Self-citationLi, Y., Tian, Z., Rizvi, S. M., Bander, N. H., & Allen, B. (2002) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500543 · Cited by 85
Nonnekens, J., Chatalic, K. L. S., Molkenboer‐Kuenen, J. D. M., Beerens, C. E. M. T., Bruchertseifer, F., Morgenstern, A., Veldhoven-Zweistra, J., Schottelius, M., Wester, H., van Gent, D. C., et al. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2016.2155 · Cited by 70
Self-citation
Cited by
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
Kostelnik, T. I., & Orvig, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 483
Radiotheranostics in oncology: current challenges and emerging opportunities
Bodei, L., Herrmann, K., Schöder, H., Scott, A. M., & Lewis, J. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00652-y · Cited by 414
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
Kratochwil, C., Fendler, W. P., Eiber, M., Baum, R., Bozkurt, M. F., Czernin, J., Delgado Bolton, R. C., Ezziddin, S., Forrer, F., Hicks, R. J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04485-3 · Cited by 387
Self-citationAn Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M., Krolicki, L., & Bruchertseifer, F. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180502104524 · Cited by 370
Self-citation225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Sathekge, M., Bruchertseifer, F., Knoesen, O., Reyneke, F., Lawal, I., Lengana, T., Davis, C., Mahapane, J., Corbett, C., Vorster, M., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4167-0 · Cited by 354
Self-citation
Metadata
- Authors
- Kratochwil, C., Bruchertseifer, F., Rathke, H., Hohenfellner, M., Giesel, F. L., Haberkorn, U., & Morgenstern, A.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2018-01-11
- Volume
- 59
- Issue
- 5
- Pages
- 795-802
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2784080506
- Cited by
- 421
- References
- 38
- FWCI
- 34.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.